Employers Retreat on GLP-1 Drug Coverage Amid Rising Costs

Employer-sponsored health insurance plans are increasingly reversing coverage for GLP-1 medications, such as Wegovy and Ozempic, due to their substantial costs. This trend is creating significant challenges for individuals relying on these drugs for weight loss and management of chronic health conditions.

While GLP-1 drugs have shown promise in treating obesity and related health issues, their high monthly cost—often hundreds of dollars if paid out-of-pocket—has made insurance coverage a critical factor for access. For a period, there was positive momentum, with projections indicating that by 2026, approximately two-thirds of private employer plans would cover these medications for weight loss. Medicare also launched a $50-per-month prescription program.

However, this outlook has shifted. Surveys indicate a significant pullback in coverage. One report from the Business Group on Health suggests at least 10 percent of employer plans that currently cover GLP-1s may discontinue them in 2027. Mercer surveys show that a percentage of large employers have already dropped coverage or are planning to do so. In Massachusetts, the number of commercially insured individuals taking these drugs fell by 50 percent between 2025 and early 2026 as private coverage declined.

Companies like PepsiCo, Starbucks, and Lowe's are among those reportedly reducing or eliminating coverage, citing the high price tag of these drugs. With two in five American adults having obesity, the potential demand for these medications is substantial.

The high cost of GLP-1 drugs impacts employer insurance plans in several ways. Insurers set annual premiums based on anticipated healthcare needs. If actual costs exceed these estimates—due to unexpected high utilization of expensive GLP-1 drugs—insurers may compensate by raising premiums for the following year. Projections suggest that GLP-1 costs could lead to a 5 to 13 percent increase in premiums, with the burden likely falling on employees. To manage these costs, many employers are implementing utilization controls, such as requiring higher out-of-pocket payments for these drugs, or ceasing coverage altogether for weight-loss indications.

Economists note that from an employer's perspective, the short-term costs of covering these medications often outweigh the long-term health benefits. Some analyses suggest that covering GLP-1s for weight loss can increase average employee health costs significantly in the first few years, with no immediate decrease in obesity-related medical events. Other studies indicate no cost savings over a five-year period. This economic calculation, while potentially rational for employers focused on immediate expenses, can leave employees facing substantial out-of-pocket costs if they wish to continue treatment.

The current situation highlights a structural issue within the American healthcare system, where insurance is often tied to employment. This model can disincentivize employers from investing in the long-term health of their workforce, especially as job mobility increases. Companies may prioritize minimizing short-term costs over long-term health investments, even if those investments could potentially reduce overall healthcare expenditures later.

The availability of affordable generic versions of these drugs is still several years away, with generic semaglutide not expected until at least 2031, and some versions even later. While the government has limited negotiating power, primarily for Medicare, comprehensive healthcare reform that could address these systemic issues is not on the immediate horizon.

The current patchwork approach to health insurance, which appears to favor short-term cost containment over sustained employee well-being, raises questions about the sustainability and equity of the US healthcare model.